Nocturnal frequency or nocturia. Polyuria
Conditions
Interventions
Intervention 1: tadalafil 5mg, daily for 12 weeks
Made in Iran. Intervention 2: placebo, daily for 12 weeks
Made in Iran.
Treatment - Drugs
tadalafil 5mg, daily for 12 weeks
Made in Iran
placebo, daily for 12 weeks
Made in Iran
Sponsors
Vice chancellor for research, Guilan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
50 Years to 149 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age above 50, refractory LUTS to life style change such as: quite smoking and limit consumption of liquid alcohol and caffeine before sleeping, having moderate physical activity. Exclusion criteria: BMI above 30kg/m2, surgery indication for BPH, urinary residual above 200CC, chronic pelvic pain syndrome (CPPS) over active bladder (OAB) urethral or bladder stone, history of pervious neurogenic bladder ureteral or bladder stone history of urethral bladder or prostate malignancy, PSA above 4 ng/ml or PSA between 4-10 ng/ml with positive biopsy for prostate malignancy, active urinary tract infection (UTI) or active sexual transmitted disease (STD)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nocturia. Timepoint: 2, 4, 8 and 12 weeks after intervention. Method of measurement: Examination and evaluation by Night Time Voiding Diary, SPSS and Quality of Life score questionnaires, and uroflowmetry (Maximum Flow Rate or Qmax). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Keivan Gholamjani Moghadam
Guilan University of Medical Sciences
Outcome results
None listed